A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC
LB Darragh, MM Knitz, J Hu, ET Clambey, J Backus… - Nature Cancer, 2022 - nature.com
Five-year survival for human papilloma virus-unrelated head and neck squamous cell
carcinomas remain below 50%. We assessed the safety of administering combination …
carcinomas remain below 50%. We assessed the safety of administering combination …
Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus–unrelated head and neck cancer: a multicenter, phase II trial
R Uppaluri, KM Campbell, AM Egloff, P Zolkind… - Clinical Cancer …, 2020 - AACR
Purpose: Pembrolizumab improved survival in patients with recurrent or metastatic head and
neck squamous-cell carcinoma (HNSCC). The aims of this study were to determine if …
neck squamous-cell carcinoma (HNSCC). The aims of this study were to determine if …
[HTML][HTML] Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head …
R Leidner, M Crittenden, K Young, H Xiao… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Checkpoint inhibitors targeting programmed death receptor-1 (PD-1) have
been tested in the neoadjuvant setting for the treatment of locoregionally advanced head …
been tested in the neoadjuvant setting for the treatment of locoregionally advanced head …
Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local–regionally advanced head and neck squamous cell carcinoma
TM Wise-Draper, S Gulati, S Palackdharry… - Clinical Cancer …, 2022 - AACR
Purpose: Patients with resected, local–regionally advanced, head and neck squamous cell
carcinoma (HNSCC) have a one-year disease-free survival (DFS) rate of 65%–69% despite …
carcinoma (HNSCC) have a one-year disease-free survival (DFS) rate of 65%–69% despite …
Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus–associated oropharynx squamous cell carcinoma
PURPOSE The purpose of this study was to determine if dose de-escalation from 60 to 66
Gy to 30 to 36 Gy of adjuvant radiotherapy (RT) for selected patients with human …
Gy to 30 to 36 Gy of adjuvant radiotherapy (RT) for selected patients with human …
[HTML][HTML] Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant …
I Tinhofer, V Budach, M Saki, R Konschak… - European journal of …, 2016 - Elsevier
Background Despite clear differences in clinical presentation and outcome, squamous cell
carcinomas of the head and neck (SCCHN) arising from human papilloma virus (HPV) …
carcinomas of the head and neck (SCCHN) arising from human papilloma virus (HPV) …
Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study
AM Chen, C Felix, PC Wang, S Hsu, V Basehart… - The Lancet …, 2017 - thelancet.com
Background Head and neck cancers positive for human papillomavirus (HPV) are
exquisitely radiosensitive. We investigated whether chemoradiotherapy with reduced-dose …
exquisitely radiosensitive. We investigated whether chemoradiotherapy with reduced-dose …
Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC).
R Uppaluri, P Zolkind, T Lin, B Nussenbaum… - 2017 - ascopubs.org
6012 Background: Pembrolizumab has efficacy in metastatic HNSCC. We hypothesized that
treatment intensification in surgically resectable HPV-negative, Stage III/IV HNSCC with …
treatment intensification in surgically resectable HPV-negative, Stage III/IV HNSCC with …
MC1675, a phase III evaluation of de-escalated adjuvant radiation therapy (DART) vs. standard adjuvant treatment for human papillomavirus associated …
DM Ma, K Price, EJ Moore, SH Patel, ML Hinni… - International Journal of …, 2021 - Elsevier
Purpose/Objective (s) We previously reported the results of a phase II clinical trial evaluating
30-36 Gy of adjuvant radiation therapy (RT) for selected patients with HPV+ OPSCC. Herein …
30-36 Gy of adjuvant radiation therapy (RT) for selected patients with HPV+ OPSCC. Herein …
[HTML][HTML] Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer
JM Redman, J Friedman, Y Robbins… - The Journal of …, 2023 - Am Soc Clin Investig
BACKGROUND Head and neck squamous cell carcinoma not associated with HPV (HPV-
unrelated HNSCC) is associated with a high rate of recurrence and poor survival …
unrelated HNSCC) is associated with a high rate of recurrence and poor survival …